Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.74 |
| ▸ | CCNC | P24863 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | CLK2 | P49760 | 1/20 | 0.63 |
| ▸ | CDK7 | P50613 | 1/20 | 0.63 |
| ▸ | CDK9 | P50750 | 1/20 | 0.63 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652150 | 1.00 | IRAK4 (0.74) | IRAK4CCNCCDK8CLK1CLK2 | |
| SCHEMBL23807932 | 0.86 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL21998097 | 0.86 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL34464405 | 0.86 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL19179644 | 0.86 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19179518 | 0.86 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL23945170 | 0.83 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL17661297 | 0.83 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL23806243 | 0.83 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL17209413 | 0.83 | IRAK4 (0.81) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3200789-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9932350-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3200789-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016053772-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885CCNC 3977/4885CDK8 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.